---
title: Measuring Droplets in Children
nct_id: NCT04518033
overall_status: COMPLETED
phase: NA
sponsor: Massachusetts General Hospital
study_type: INTERVENTIONAL
primary_condition: Droplet Spread
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04518033.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04518033"
ct_last_update_post_date: 2022-01-20
last_seen_at: "2026-05-12T06:42:10.613Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Measuring Droplets in Children

**NCT ID:** [NCT04518033](https://clinicaltrials.gov/study/NCT04518033)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 23
- **Lead Sponsor:** Massachusetts General Hospital
- **Collaborators:** Harvard School of Public Health (HSPH)
- **Conditions:** Droplet Spread
- **Start Date:** 2021-04-03
- **Completion Date:** 2021-04-23
- **CT.gov Last Update:** 2022-01-20

## Brief Summary

This study will measure the size and quantity of respiratory particle production in children under a variety of conditions, including face coverings/masks and various common activities.

## Eligibility

- **Minimum age:** 3 Years
- **Maximum age:** 17 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

\- Age 3 to 17 years

Exclusion Criteria:

* Chronic neuromuscular conditions that affect respiration
* Tracheostomy tube
* Unable to wear a face mask
```

## Arms

- **Face covering use** (EXPERIMENTAL) — Participants will be provided various commercially available face coverings

## Interventions

- **Various commercially available face coverings** (DEVICE) — Various commercially available face coverings

## Primary Outcomes

- **Respiratory particle production** _(time frame: 2 hours)_

## Locations (1)

- Massachusetts General Hospital, Boston, Massachusetts, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.massachusetts general hospital|boston|massachusetts|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT04518033.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT04518033*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*